The p53 Inhibitor MDM2 Facilitates Sonic Hedgehog-Mediated Tumorigenesis and Influences Cerebellar Foliation

Reem Malek1, Jennifer Matta2, Natalie Taylor1, Mary Ellen Perry3, Susan M. Mendrysa1*

1 Department of Basic Medical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America, 2 Laboratory Animal Sciences Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America, 3 Laboratory of Protein Dynamics and Signaling, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America

Abstract

Disruption of cerebellar granular neuronal precursor (GNP) maturation can result in defects in motor coordination and learning, or in medulloblastoma, the most common childhood brain tumor. The Sonic Hedgehog (Shh) pathway is important for GNP proliferation; however, the factors regulating the extent and timing of GNP proliferation, as well as GNP differentiation and migration are poorly understood. The p53 tumor suppressor has been shown to negatively regulate the activity of the Shh effector, Gli1, in neural stem cells; however, the contribution of p53 to the regulation of Shh signaling in GNPs during cerebellar development has not been determined. Here, we exploited a hypomorphic allele of Mdm2 (Mdm2puro), which encodes a critical negative regulator of p53, to alter the level of wild-type MDM2 and p53 in vivo. We report that mice with reduced levels of MDM2 and increased levels of p53 have small cerebella with shortened folia, reminiscent of deficient Shh signaling. Indeed, Shh signaling in Mdm2-deficient GNPs is attenuated, concomitant with decreased expression of the Shh transducers, Gli1 and Gli2. We also find that Shh stimulation of GNPs promotes MDM2 accumulation and enhances phosphorylation at serine 166, a modification known to increase MDM2-p53 binding. Significantly, loss of MDM2 in Ptc1+/− mice, a model for Shh-mediated human medulloblastoma, impedes cerebellar tumorigenesis. Together, these results place MDM2 at a major nexus between the p53 and Shh signaling pathways in GNPs, with key roles in cerebellar development, GNP survival, cerebellar foliation, and MB tumorigenesis.

Introduction

The cerebellum is a highly organized structure that coordinates motor, linguistic and cognitive functions [1]. The internal granular layer (IGL) of the cerebellum contains the majority of the neurons of the brain, and its proper organization requires precise control of both the extent and timing of the number of intricate processes, including the migration, proliferation, and differentiation of granular neuronal precursors (GNPs) [2]. In mice, GNPs are derived from the rhombic lip region of the fourth ventricle prior to embryonic day 14.5 and migrate dorsally over the cerebellar primordium to form the nascent external granular layer (EGL) [3]. The development of the cerebellum continues during the first weeks (mice) or months (humans) after birth, during which time GNPs continue to proliferate prior to their differentiation into mature granule cell (GC) neurons [4,5]. Improper GNP maturation can result in defective foliation, which is associated with defects in motor coordination [6,7], or in medulloblastoma, the most common childhood brain tumor [8].

Mitogenic signaling by the Sonic Hedgehog (Shh) pathway is critical for GNP proliferation and expansion of the EGL in the post-natal period of cerebellar development [9,10,11]. During this time, Shh is secreted by Purkinje cells and binds to its receptor, Patched (Ptc), which is expressed on GNPs [12]. In the absence of Shh, Ptc inhibits the signaling activity of Smoothened (Smo). Binding of Shh to Ptc alleviates Smo repression, thereby triggering activation of the Gli (Gli1, 2, and 3) family of transcription factors [13,14]. The proliferative effects of Shh are likely mediated through the transcriptional regulation of Shh target genes that include several transcription factors (e.g. NMy) [15] and downstream cell cycle regulatory proteins (e.g. CyclinD1) [16]. Shh signaling is down-regulated in GNPs at the later stages of cerebellar development through a mechanism which is not well understood, and this failure of GNPs to respond to Shh correlates with their cell cycle exit and subsequent differentiation into mature GC neurons that migrate inward to form the IGL [4,5].

Aberrantly constitutive Shh signaling has been implicated in the etiology of several cancers, including medulloblastoma (MB) [17,18,19,20,21]. One subtype of MB is presumed to arise following the dysregulation of the normal developmental program of a GNP [22]. In agreement with this view, Shh signaling is aberrantly activated in >60% of MB tumors [23]. Ptc1, an inhibitory component of Shh signaling, acts as a tumor suppressor [24] and germ-line mutations in Ptc1 promote MB formation in...
both humans and mice [17,18]. In MB tumors that form in \(Ptch1^{+/−}\) mice, Shh signaling is constitutively active and blocking this signal with a Shh-antagonist promotes tumor regression [25,26], highlighting the importance of Shh signaling in the initiation and maintenance of this tumor type. Despite the prevalence of Shh dysregulation in MB, mutations in known components of the Shh signaling pathway have been identified in only \(\sim 10-25\%\) of sporadic human MB [27], leaving the genetic basis for most MB tumors unexplained. This gap in knowledge may be filled through the identification of other genes and pathways that collaborate with Shh signaling in GNP maturation.

The p53 pathway is a leading candidate collaborator with Shh in both cerebellar development and MB. A role for p53 inactivation in MB pathogenesis is suggested by the increased incidence of MB in people with Li Fraumeni syndrome, which is caused by germ-line mutation in \(p53\) [28,29], as well as in rodent models in which \(p53\) is co-deleted with genes such as \(Ptch1\) [30,31]. \(p53\) induces multiple anti-proliferative processes, including cell cycle arrest [32] and apoptosis [33], thereby effectively limiting the survival of potentially pre-neoplastic cells. Under physiological conditions, the level and activity of p53 is kept under strict negative control by the ubiquitin ligase, MDM2. Mice lacking Mdm2 die in utero due to massive, p53-dependent apoptosis and this phenotype is fully rescued by deletion of \(p53\) [34,35]. In contrast, expression of a \(p53\) mutant, \(p53R172P\), that can stimulate growth arrest but not apoptosis, only partially rescues the phenotype, such that a subset of pups survives to postnatal day 12–15 [36,37]. These mice exhibit a severe impairment in the proliferation of GNPs, resulting in shortened folia and diminished IGL cell numbers, strongly implicating MDM2 and p53 in cerebellar development. However, this study did not assess the influence of MDM2 on either \(p53\)-mediated apoptosis or Shh signaling during cerebellar development. Furthermore, the early death of these mice precluded an assessment of the consequences of MDM2 loss in tumorigenesis or behavior [36,37].

Here, we took advantage of a unique hypomorphic \(Mdnm\) allele (\(Mdnm^{2mm}\)) to examine the contribution of this ubiquitin ligase to cerebellar development in the presence of its target, wild-type \(p53\) [38]. This study reveals a threshold amount of MDM2 is required to inhibit the apoptotic function of \(p53\) and facilitate Shh signaling in GNPs. Moreover, Shh signaling regulates the level of MDM2 in GNPs, suggesting a complex interplay between the \(p53\) and Shh pathways in these important neuronal precursor cells. Together, these findings place MDM2 at a critical node between the p53 and Shh pathways in cerebellar development and tumorigenesis.

### Materials and Methods

#### Ethics Statement

Mouse experiments were approved in advance by either the Purdue University Animal Care and Use Committee (protocol number 08-065; S.M.M.) or the NCI Frederick Animal Science Program (protocol number 08-006; M.E.P.) and performed in compliance with national regulatory standards.

#### Mouse breeding and genotyping

Mouse strains used in this study have been described previously. \(Mdnm^{2mm/+}\) and \(Mdnm^{2mm/A^T}\) mice were maintained on a 129/Sv and C57BL/6 background, respectively, and interbred to obtain experimental, F1 hybrid \(Mdnm^{2mm/A^T}\) and wild-type mice [38]. \(Ptch1^{+/−}\) heterozygotes on both 129/Sv and C57BL/6 backgrounds were obtained from Karlyne Reilly of NCI-Frederick [39]. B6;129-Ptch1\(^{Puro}\)/J (referred to as \(Ptch1^{Puro}\)) mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) [18]. For analysis of pre-neoplastic lesions (PNLs), \(Ptch1^{+/−}\cdot Mdnm^{2mm/+}\) and \(Ptch1^{+/−}\cdot \text{Mdm2}^{puro/\text{A^T}}\) mice were bred to obtain mice that express one of four levels of MDM2. Mice used for the PNL study were maintained on a mixed 129/Sv\(\times\)C57BL/6 background. \(p53\), \(Ptch1\) and \(Mdm2\) alleles were genotyped as described previously [30,39,40].

#### Behavioral analysis

Eighteen wild-type and 17 mutant 4-month-old mice were assessed for gross neurological function, motor control, and balance using a series of well established behavioral tests [41]. To evaluate motor coordination and balance, mice were tested for the ability to stay on a cylindrical drum (Rotarod) that was either rotating at a constant speed (7 rpm) or accelerating (from 3.5 rpm to 35 rpm). In addition, 16 wild-type and 15 mutant 4-week-old mice were assessed on a subset of the tests and 8 wild-type and 5 mutant pups were assessed daily for the ability to right themselves immediately, starting at P7.

#### Morphometric analysis

To determine the relative sizes of the white matter and IGL in adult cerebella, midsagittal sections from wild-type and \(Mdnm^{2mm/A^T}\) mice were assessed. The areas of both layers were estimated using Image-Pro Plus v6.2 software (Media Cybernetics, Bethesda, MD). Images were acquired using a ScanScope CS (Aperio, Vista, CA) slide scanner at 40×. Areas of interest within the digital slides were extracted as TIFs at 100% resolution using ImageScope (Aperio, Vista, CA). The areas of the white matter and of the IGL were each determined by user-assisted region-of-interest selection and thresholding.

#### Analysis of proliferation and apoptosis

For BrdU analysis of P0 pups, 95 mg BrdU/kg body weight was injected intraperitoneally one hour prior to necropsy. Brains were fixed for 24 hours in 10% neutral buffered formalin and embedded with paraffin and 5 micron sections were prepared. BrdU was detected immunohistochemically using antibody A21301MP (Invitrogen, Carlsbad, CA); TUNEL assay was performed using ApoTag Kit #S7100 (Millipore, Billerica, MA). To determine the percentage of BrdU-positive and TUNEL-positive EGL cells, the area of the EGL was estimated as described under morphometric analysis. The EGL was outlined manually using ImageScope software and the number of pixels representing hematoxylin-positive nuclei within that outline was determined using ImagePro software. The number of BrdU-positive EGL cells was estimated by automated determination of the number of pixels representing diaminobenzidine-positive nuclei as measured by signals equal to or greater than the average threshold range for the BrdU signal measured across several samples. Data were extracted as pixel area for both the EGL and BrdU signals. The percentage of BrdU-positive cells within the isolated EGL layer segmentation was determined by dividing the number of pixels representing BrdU-positive nuclei by the number of pixels representing EGL nuclei and multiplying by 100 for each sample. TUNEL-positive cells were counted under a microscope at 40× power. To calculate the percentage of EGL cells that was apoptotic, the EGL area was converted to cell number using the average EGL cell area (in pixels).

#### Immunohistochemistry

Sagittal sections were stained with hematoxylin and eosin (H&E). Immunohistochemical detection of \(p53\), Calbindin-D-28K, and CyclinD1 was performed using primary rabbit
antibodies NCL-p53-CM5p, (Vector Laboratories, Burlingame, CA); KD-15 (Chemicon, Carpenteria, CA); and RB-212-P1 (Lab Vision/Thermo Fisher Scientific, Fremont, CA), respectively.

Pre-neoplastic lesion (PNL) analysis

Pchipl−/− mice expressing one of four levels of MDM2 were euthanized at 3 weeks of age and cerebella were removed and fixed overnight in 4% paraformaldehyde and embedded in paraffin. The entire cerebellum of each animal was sagittally sectioned at 200 μm intervals. PNLs were identified morphologically in H&E stained sections as areas of focal or diffuse hyperplasia. Sections were analyzed and PNLs scored blindly and independently by 2–3 observers.

Granular neuronal precursor (GNP) cell isolation

GNP cultures were prepared from pooled P5 cerebellum of mice and stimulated with either 3 μg/ml recombinant Shh (20 kD amino-terminal signaling peptide; R&D Systems, Minneapolis, MN) or vehicle control as described by [13]. Shh stimulation of GNP proliferation was confirmed by adding 10 μM BrdU to the GNP culture media for 2 h followed by fixation in 70% ethanol. Proliferating cells that incorporated BrdU during the labeling period were identified using an anti-BrdU antibody and detected by immunofluorescent microscopy. The fold change in cell proliferation was calculated as the ratio of the percent BrdU-positive cells in cultures treated with Shh compared to vehicle only controls. At times post-Shh stimulation GNPs were washed twice in cold PBS and snap frozen in liquid nitrogen for subsequent RNA and protein analyses.

For the analysis of Shh and p53 target gene expression in GNPs that differ in the level of MDM2 expression, GNPs were isolated in cold PBS and snap frozen in liquid nitrogen for subsequent controls. At times post-Shh stimulation GNPs were washed twice in cold PBS and lysed in radioimmunoprecipitation assay (RIPA) buffer [42] supplemented with a protease inhibitor cocktail (Roche, Indianapolis, IN). Protein concentrations were determined using the DC Protein Assay (Bio-Rad, Hercules, CA). The primary antibodies for Western analyses were: anti-MDM2 (2A10; ab16895), anti-Gli (ab7523), anti-Gli2 (ab26056) (all from Abcam, Cambridge, MA) and anti-Actin (clone AC-15; Sigma, St. Louis, MO). Primary antibodies were revealed using the appropriate sheep anti-mouse or anti-rabbit secondary antibodies conjugated to peroxidase and enhanced chemiluminescence (ECL) (GE Healthcare, Piscataway, N J).

Real-time and RT-PCR

Total RNA isolated from cerebellar tissue was analyzed by reverse transcription (RT)- and real-time PCR. Whole cerebella were homogenized in TriZol (Invitrogen, Carlsbad, CA) and total RNA isolated per the manufacturer’s instructions. Total RNA (2 μg) was used to generate cDNA using Transcripter Reverse Transcriptase (Roche, Indianapolis, IN) and random hexamers. The following primers for mouse Gli1, Nmyc, CyclinD1, p21, DAPK, CyclinG, Mdm2, and Tubb5 control were designed to amplify products spanning gene introns with assistance of the Primer3 website: Gli1, 5′ GTG TAC CAC ATG ACT CTA CTC GGG 3′ and 5′ TCA TAC ACA GAC TCA CTC GGC TCA CGG 3′; Nmyc, 5′ AGC ACC TCC GGA GAG GAT AC 3′ and 5′ AAG TGG TTA CCG CCT TGT TG 3′; CyclinD1, 5′ TCA AGA CCG AGG AGA CCT GT 3′ and 5′ CTC CTC TTC GCA CTT CTG CT 3′; p21, 5′ TGG TCG CTT TG TCT GTC ACT CT 3′ and 5′ TGC CAT CTG GCT CTT CTA CCA GAC 3′; DAPK, 5′ TGG TAC AAC AGC TGAC TAC AGC GC 3′ and 5′ ATG GCC TGA TCG CAG ACA ACG A 3′ and Tubb5, 5′ TGG GAC TAT GGA CTC GTG TC 3′ and 5′ AAA GGC TTG CAG GCA ATC AGC 3′. Real-time and endpoint PCR were conducted to confirm amplification of a single product of the expected size. Real-time PCR reactions were set up using ABI SYBR green PCR Master Mix (ABI, Foster City, CA) and run on an ABI 7000 Sequence Detection System. Data were analyzed using ABI GeneAmp SDS software. Relative gene expression levels were calculated using the formula 2−ΔΔCt with Tubb5 as a loading control and wild-type expression values as the calibrator. Analyses were performed in triplicate for three mice per Mdm2 genotype.

One-way analysis of variance (ANOVA) test was done using SPSS 16.0 (SPSS Inc., Chicago, IL) with P-value<0.05 considered significant.

Results

The Mdm2puro allele is globally hypomorphic in expression

During the production of a conditional Mdm2 allele, we fortuitously generated a novel hypomorphic allele, Mdm2puro (Fig. 1A) [38]. Northern blot analyses of RNA derived from various tissues obtained from mice carrying one Mdm2puro allele and one null Mdm2 allele (Mdm2puro−/−) or Mdm2puro and one null Mdm2 allele (Mdm2puro/puro) [38]; collectively referred to as Mdm2puro, revealed that expression of full-length Mdm2 mRNA was significantly reduced in all tissues examined including spleen, thymus, kidney, liver, and brain [38]. Western blot analysis of protein extracts prepared from Mdm2puro/mutnull tissues confirmed reduced expression of full-length MDM2 protein in testes [38], thymus [43], and brain (Fig. 1). Consistent with the previously reported decrease in Mdm2 mRNA in brain tissue, MDM2 protein levels are reduced three-fold in whole brain and four-fold in isolated cerebellar granular neuronal precursors (GNPs) (Fig. 1B,C). No aberrant Mdm2 mRNAs or truncated MDM2 proteins have been identified from the Mdm2puro allele. The diminished expression of MDM2 from the Mdm2puro allele is dependent upon insertion of the Puro gene into the non-coding intron 6 of the Mdm2 gene [38]. The mechanism by which the Puro gene diminishes Mdm2 expression is not fully understood but may involve transcriptional interference as has been observed for other targeted alleles [44]. Together, these data establish that the Mdm2puro allele is globally hypomorphic for full-length wild-type MDM2 expression.

By combining wild-type, null, and hypomorphic alleles of Mdm2 we are able to generate mice that differ in the level of MDM2 expression (Fig. 1). Importantly, a 70% decrease in the level of MDM2 is sufficient for survival but results in multiple overt p53-dependent phenotypes in Mdm2puro/mutnull mice, including reduced body size and lymphopenia that are not manifest in mice with a more modest decrease in MDM2 [38]. Mdm2puro/mutnull mice thus provide a unique model for perturbing MDM2 and p53 function.
in the developing cerebellum in order to assess their impact on Shh signaling.

Hypoplasia and aberrant foliation in adult Mdm2puro/Δ7-9 cerebella

Macroscopic examination of brains from adult Mdm2puro/Δ7-9 mice revealed cerebella that were strikingly reduced in size. At 4 months of age, both male and female Mdm2puro/Δ7-9 mice showed a greater than two-fold reduction in cerebellar mass (Fig. 2A). This decrease was more profound than the decrease in overall brain weight (33% for males and 35% for females; Fig. 2B) or body weight (16% for males and 23% for females; Fig. 2C), indicating that the cerebellum is especially sensitive to a decrease in the level of MDM2 and Shh signaling.

Delayed formation of fissures in Mdm2puro/Δ7-9 cerebella

Post-natal expansion of the EGL continues for approximately three weeks, and is necessary for proper foliation. Previous studies have shown the cerebellar surface of outbred Swiss Webster embryos is smooth at E16.5, but develops four principal fissures and five cardinal lobes by E18.5 [6]. Two additional fissures form by P3, subdividing both the anterobasal lobe and lobe VI. Foliation appears to occur slightly earlier in wild-type F1 hybrid 129Sv/C57BL6 mice as by P0, the four principal fissures have formed, as have two additional fissures separating the anterobasal lobe and lobe VI (Fig. 3A). In contrast, P0 Mdm2puro/Δ7-9 mice have only two primary fissures (Fig. 3B). Although precuneate and primary fissures were apparent in all Mdm2puro/Δ7-9 mice at P0, the secondary and posterolateral fissures were not often visible. Moreover, all fissures were shallow in newborn Mdm2puro/Δ7-9 mice. Foliation depends on thickening of the EGL layer at specific anchor points [6], one or more of which appears to be missing in P0 Mdm2puro/Δ7-9 mice. Indeed, the number of EGL cells was reduced three-fold in P0 Mdm2puro/Δ7-9 mice (P<0.001), indicating that an insufficient number of GNPs may be available to form the anchor points and to extend the lobules. Superimposition of traces of mid-sagittal sections from P0, P7, and adult mice revealed that the appearance of the secondary and posterolateral fissures was delayed in Mdm2puro/Δ7-9 mice and that all fissures remained shallow throughout development (Fig. 3C,D). The shallow principal fissures at birth (P0) and delayed lobularization of Mdm2puro/Δ7-9 mice are reminiscent of the foliation defects observed in mice with decreased Shh signaling [45].
Impaired expansion of the EGL in Mdm2puro/Δ7-9 mice

By P7, the EGL of wild-type mice has reached its maximal thickness and the IGL has begun to form as GNP s differentiate and migrate inward past the Purkinje cells. Cerebella from Mdm2puro/Δ7-9 mice had a thinner EGL than that of wild-type mice, which had expanded to an 8–10 cell thick layer (Fig. 4A,B,D,E). Mdm2puro/Δ7-9 EGL cells appeared capable of differentiating, as the inner EGL of both wild-type and Mdm2puro/Δ7-9 mice was negative for CyclinD1, a marker of undifferentiated GNP s (Fig. 4G,H). Immunostaining for Calbindin-D-28K revealed that, by P7, the EGL of wild-type mice had adopted a uniform monolayer with dense dendritic arborization (Fig. 4J). However, in Mdm2puro/Δ7-9 cerebella, the Purkinje cells remained multi-layered and disorganized with stunted dendritic arborization (Fig. 4K). As the position of Purkinje cells within the cerebellum is informed by the expanding folia, these results provide additional support for a diminished EGL cell number as the underlying basis for the observed defects in foliation in Mdm2puro/Δ7-9 cerebella.

P53-dependence of cerebellar defects of Mdm2puro/Δ7-9 mice

Consistent with the reduction in the level of the MDM2 ubiquitin ligase in Mdm2puro/Δ7-9 cerebella, the level of p53 protein was elevated, as revealed by the increased percentage of EGL cells immunoreactive for p53 (Fig. 4N). To establish whether increased p53 activity was responsible for the diminished granular layer cell numbers and foliation defects of Mdm2puro/Δ7-9 mice, cerebella from Mdm2puro/Δ7-9 mice lacking p53 were assessed. Mdm2puro/Δ7-9 Δp53 mice and wild-type cerebella were indistinguishable in size and morphology (Fig. 4A,C). Histological analysis showed that in Mdm2puro/Δ7-9 Δp53 mice, foliation was normal, as was the thickness of both the EGL and IGL (Fig. 4C,D,F). Morphometric analysis of the EGL revealed that Mdm2puro/Δ7-9 Δp53 mice had a 73% decrease in the number of EGL cells (P<10^-5) whereas Mdm2puro/Δ7-9 Δp53 mice had an insignificant (3%) increase when compared to wild-type mice (P=0.40). Similarly, the number and organization of the Purkinje cells was rescued in Mdm2puro/Δ7-9 Δp53 mice (Fig. 4K,L). Whereas the number of Purkinje cells was reduced 33% in Mdm2puro/Δ7-9 Δp53 mice (P=0.00014), it was insignificantly reduced in Mdm2puro/Δ7-9 Δp53 mice (11%; P=0.14 compared to wild-type). Together, these results indicate that MDM2 protects the processes of GNP expansion and cerebellar foliation by inhibiting p53.

Decreased survival of Mdm2puro/Δ7-9 granule neuron precursors

Two physiological outcomes associated with heightened p53 activity are growth arrest and apoptotic cell death, both of which could contribute to a decrease in the number of GNP s. To investigate whether a reduction in cell proliferation contributes to the diminished GNP population in P0 Mdm2puro/Δ7-9 mice, we performed in vivo labeling with 3-bromo-2-deoxyuridine (BrdU). We found that the EGL of both wild-type and Mdm2puro/Δ7-9 mice was proliferative, but that there were fewer BrdU-positive GNP s in the MDM2-deficient cerebella. The absolute number of proliferating BrdU-positive cells in the EGL in P0 Mdm2puro/Δ7-9 cerebella was only 23% of that found in wild-type controls (Fig. 5A,B,D,E). However, when a four-fold decrease in the number of GNP s in P0 Mdm2puro/Δ7-9 mice (Fig. 5C) was taken into account, the relative number of BrdU-positive GNP s was 91% that of wild-type controls (Fig. 5A,B,D,E). Although the decrease in the number of BrdU-positive Mdm2puro/Δ7-9 GNP s was statistically insignificant (P=0.082) as compared to wild-type, GNP s proliferate at a high rate during the first week of post-natal cerebellar development.
Thus, even a modest decrease in proliferation could significantly reduce the total number of GNPs generated and hence negatively impact cerebellar size and foliation.

As MDM2 also limits the apoptotic function of p53, we next assessed whether in Mdm2puro/D7-9 mice GNP survival was impaired. To identify apoptotic cells, we performed terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in situ. Quantitative analysis of cell death revealed an increase in the number of TUNEL-positive cells in the EGL of Mdm2puro/D7-9 cerebella (Fig. 5G,H). In contrast to the moderate decrease in cell proliferation, the percentage of TUNEL-positive EGL cells was increased 12.4-fold in the Mdm2puro/D7-9 cerebellum at P0 (P = 0.033; Fig. 5I). This increase in apoptosis persisted for at least seven days, as Mdm2puro/D7-9 mice had a 20-fold increase in the fraction of EGL cells that were apoptotic at P7 (n = 3, P<0.035; data not shown). Consistent with the normal size and foliation of Mdm2puro/D7-9 Gli2−/− cerebella, the increase in apoptosis in the Mdm2puro/D7-9 EGL is p53-dependent, as demonstrated by the normal (e.g., equivalent to wild-type) fraction of GNPs that were TUNEL-positive in the EGL of P7 Mdm2puro/D7-9 mice lacking p53 (n = 3, P = 0.39 when compared to wild-type; data not shown). Together, these data indicate that increased apoptosis rather than growth arrest is the main contributor to the diminished EGL in Mdm2puro/D7-9 mice.

**Attenuated Sonic Hedgehog signaling in Mdm2puro/D7-9 cerebella**

As noted in the previous sections, we observed a striking similarity between the cerebellar phenotypes of Mdm2puro/D7-9 mice and those lacking Shh [11] or its downstream effectors (e.g. Gli2, NMyC, CyclinD2) [45,46,47]. For example, the defects in EGL expansion, Purkinje cell layer organization and foliation are similar to those in which Gli2 has been deleted conditionally [45]. These observations prompted us to examine if Shh signaling was altered in the cerebellum of Mdm2puro/D7-9 mice. We therefore measured the level of expression of known targets of Shh-activated transcription factors. Quantitative real-time PCR analyses revealed that expression of each of the direct Shh target genes Gli1 and NMyC [15], as well as the indirect Shh target CyclinD1 [48] was reduced 2- to 3-fold in P5 Mdm2puro/D7-9 cerebella compared to wild-type control cerebella (Fig. 6A). As the defects in EGL expansion, Purkinje cell layer organization and foliation are similar to those in which Gli2 has been deleted conditionally [45]. These observations prompted us to examine if Shh signaling was altered in the cerebellum of Mdm2puro/D7-9 mice. We therefore measured the level of expression of known targets of Shh-activated transcription factors. Quantitative real-time PCR analyses revealed that expression of each of the direct Shh target genes Gli1 and NMyC [15], as well as the indirect Shh target CyclinD1 [48] was reduced 2- to 3-fold in P5 Mdm2puro/D7-9 cerebella compared to wild-type control cerebella (Fig. 6A). As the

![Figure 3. Foliation defects in P0 mice.](image-url)
Figure 4. Cerebellar abnormalities of Mdm2puro/Δ7-9 mice are rescued by loss of p53. Midsagittal sections of cerebella from wild-type (A,D,G,J,M), Mdm2puro/Δ7-9 (B,E,H,K,N), and Mdm2puro/Δ7-9;p532/2 (C,F,I,L,O) mice at P7. (A–F) H&E staining shows a thin EGL and sparsely-populated IGL in Mdm2puro/Δ7-9 cerebella. (G–I) MDM2 deficiency does not appear to block GNP differentiation as immunohistochemical staining for CyclinD1 selectively marks undifferentiated GNPs of the outer, but not inner, EGL. (J–L) Mdm2puro/Δ7-9 Purkinje cells stained with anti-Calbindin D-28K have stunted arborization of the dendrites and have failed to form a uniform monolayer as seen in wild-type controls. Mdm2puro/Δ7-9;p532/2 (M–O) Immunohistochemical staining for p53 reveals an increase in the number of GNPs staining positively for p53 in the EGL of Mdm2puro/Δ7-9 mice. Mdm2puro/Δ7-9;p532/2 mice are phenotypically indistinguishable from wild-type mice, highlighting the importance of MDM2 for limiting p53 function in cerebellar development.

doi:10.1371/journal.pone.0017884.g004
number of GNPs present in Mdm2puro/D7-9 mice is equivalent to that in wild-type mice (Fig. 6B), the reduction in Shh target gene expression in these mice cannot be explained by an under- 
representation of GNPs. Moreover, in the same samples, p53 target gene expression was increased as expected. The finding of reduced Shh target gene expression is consistent with a recent model in which enhanced p53 activity down-regulates Shh 
signaling [49].

**Gli1 and Gli2 proteins are decreased in Mdm2puro/D7-9 GNPs**

The Gli proteins are critical mediators of the Shh signal. To begin to establish the underlying basis by which a low level of MDM2 limits the output of Shh signaling in Mdm2puro/D7-9 cerebellum, we analyzed the level of Gli1 and Gli2 in Mdm2puro/D7-9 GNPs. Consistent with the reduction of Gli1 mRNA in the Mdm2puro/D7-9 cerebellum (Fig. 6A), the steady-state level of endogenous Gli1 is reduced seven-fold in Mdm2puro/D7-9 GNPs as compared to wild-type GNPs (Fig. 6C). Significantly, the steady-state level of endogenous Gli2 protein was reduced two-fold in GNPs in which MDM2 is expressed at only -25% the level of wild-type (Fig. 6C). Our finding that Gli1 and Gli2 expression is reduced in Mdm2puro/D7-9 GNPs in which p53 function is heightened suggests a model in which p53 attenuates Shh signaling output by negatively regulating Gli activity.

**Shh signaling induces MDM2**

Activation of the Shh pathway in C3H10T1/2 mesenchymal and mouse embryonic fibroblast (MEF) promotes phosphorylation of MDM2 at serine 166 (p-MDM2 S166), a modification that 
enhances the ability of MDM2 to bind to and limit p53 function [50,51,52]. To determine whether MDM2 is similarly regulated by Shh signaling in GNPs, we employed primary cultures from 
cerebellar homogenates. Derived from mice at P5, 
85% of the 
cells in cerebellar homogenates are GNPs [15,48]. In our hands, 
1.5% of cells in cultured from wild-type mice were GFAP 
+ glial 
cells (n = 2, data not shown). Addition of recombinant Shh-N to 
the culture medium increased proliferation, 
4.9-fold based on 
BrdU incorporation (Fig. 7A,B), consistent with other studies [15]. 
Concomitant with enhanced GNP proliferation, expression of the 
Shh-target Gli1 was increased greater than 10-fold (Fig. 7C). 
Cultured GNPs thereby retain their in vivo characteristics and thus provide a good experimental system with which to dissect the molecular pathways that control their behavior. Using this experimental system, we discovered that both total MDM2 and its activated form, p-MDM2S166, accumulated 3- to 4-fold in
Figure 6. Shh signaling is attenuated concomitant with p53 activation in Mdm2\textsuperscript{2/\textmu ro/\textDelta 7-9} cerebella. (A) Expression of Shh target genes (Gli1, NMyc, CyclinD1) and p53 target genes (p21, DAPK, CyclinG) in whole cerebella was determined by real-time PCR and normalized to Tubb5. Graphed is the average fold change in gene expression of Shh- and p53-target genes in whole cerebella of P5 mice with the indicated Mdm2 genotype relative to wild-type controls (n = 3, *P < 0.05). (B) Histogram showing the total number of GNPs isolated from cerebella of mice of the indicated Mdm2 genotype at P5 (n = 3–8, *P < 0.05). (C) WB analysis of Gli1 and Gli2 in GNPs isolated from P5 mice of the indicated Mdm2 genotype. WB for actin confirms equal loading.

Figure 7. Regulation of MDM2 by Shh in cultured wild-type GNPs. (A) IHC for BrdU-incorporating cells in vehicle-treated (−Shh) and stimulated (+Shh) GNPs. Total nuclei labeled by DAPI. (B) Graphed is the average fold change in the percentage of GNPs immunoreactive for BrdU in Shh stimulated versus vehicle control cultures (n = 3). (C) Expression of Mdm2 and the Shh target gene, Gli1, was quantified by real-time PCR and normalized to Tubb5. Graphed is the relative fold change in expression of Mdm2 and Gli1 in wild-type GNPs cultured in the presence of Shh (+) or vehicle (−). (D) WB analysis of MDM2 and p-MDM2\textsuperscript{S166} in GNPs treated with Shh (+) or vehicle (−). WB for actin confirms equal loading of protein.

doi:10.1371/journal.pone.0017884.g006
doi:10.1371/journal.pone.0017884.g007
GNPs stimulated by Shh, without a corresponding increase in Mdm2 mRNA (Fig. 7C,D).

**Decreased incidence of pre-neoplastic lesions in Ptc1<sup>+/−</sup>; Mdm2<sup>puro/Δ7-9</sup> mice**

Deregulation of the Shh pathway is implicated in >60% of MB [23]. Based on our finding that MDM2 promotes Shh signaling as well as GNP survival during cerebellar development, we hypothesized that MDM2 also plays a critical role in Shh-induced cerebellar disease. As a test of this hypothesis, we performed a genetic loss-of-function study using Ptc1<sup>+/−</sup> mice, a model of Shh-induced human MB [18]. While only a subset of Ptc1<sup>+/−</sup> mice develop MB, close to 100% of Ptc1<sup>+/−</sup> mice exhibit clusters of highly proliferative cells at the surface of the cerebellum at 3 weeks of age, by which time the majority of GNPs in wild-type mice have stopped dividing, differentiated and migrated into the IGL as mature GCs [18,40,53]. Orthotopic transplantation and fate mapping experiments support the identity of these proliferating cells as uncommitted pre-neoplastic cells that are susceptible to transformation [54]. These clusters of proliferative cells therefore represent pre-neoplastic lesions (PNLs) for MB in this mouse model. To determine the requirement for MDM2 in the formation of PNLs, we examined cerebella of 3-week-old Ptc1<sup>+/−</sup> mice that differed in the level of MDM2. In agreement with prior studies, no PNLs were present in the cerebellum of wild-type mice (n = 5), whereas 100% of Ptc1<sup>+/−</sup> mice with a wild-type level of MDM2 (n = 10) exhibited multiple PNLs in the cerebellum (Fig. 8). Strikingly, despite analysis of six cerebella from Ptc1<sup>+/−</sup>; Mdm2<sup>puro/Δ7-9</sup> mice, we have yet to identify any with a PNL. These results indicate that an approximately 70% reduction in Mdm2 expression completely abrogates formation of Shh-induced PNLs in Ptc1<sup>+/−</sup> mice (Fig. 8A–D). These results suggest that MDM2 plays a critical role in GNPs during Shh-mediated MB formation.

![Figure 8](image-url)

**Figure 8.** Shh-induced pre-neoplastic lesion (PNL) formation in the cerebellum is significantly decreased in Ptc1<sup>+/−</sup> mice expressing ~30% the wild-type level of MDM2. (A–C) Shown are H&E stained sagittal sections of cerebella obtained from 3-week-old (A) wild-type, (B) Ptc1<sup>+/−</sup>, and (C) Ptc1<sup>+/−</sup>; Mdm2<sup>puro/Δ7-9</sup> mice. PNLs as indicated by the arrow and outlined by the dashed blue line in (B) are composed of small, round tightly clustered cells with a high nucleus:cytoplasmic ratio located superficial to the molecular layer either on the surface of the cerebellum or in a fissure between adjacent folia. Ptc1<sup>+/−</sup>; Mdm2<sup>puro/Δ7-9</sup> mice (C) fail to develop PNLs. (D) Quantification of PNLs observed in 3-week-old Ptc1<sup>+/−</sup> and Ptc1<sup>+/−</sup>; Mdm2<sup>puro/Δ7-9</sup> mice. (E) Model for crosstalk between p53 and Shh pathways in cerebellar development. During GNP development, Shh stimulates proliferation through the positive regulation of the Gli family of transcription factors. P53 promotes apoptosis and concomitantly interferes with Gli function, attenuating the proliferative effects of Shh. Shh regulates MDM2, to keep p53 activity in check, allowing GNPs to expand in response to Shh signaling.

doi:10.1371/journal.pone.0017884.g008
Discussion

Here we have taken advantage of a unique series of Mdm2 alleles to obtain a comprehensive understanding of MDM2 function in the cerebellum. Whereas Mdm2-null mice die early in embryogenesis [34,35], Mdm2puro/7-9 compound heterozygotes, which express only ~30% of the wild-type level of MDM2 are viable but display multiple cerebellar defects including decreased expansion of the number of GNPs within the EGL, disorganization of the Purkinje cell layer, and aberrant foliation. In contrast, ~50% expression of MDM2, as in Mdm2puro/7-9 mice, is sufficient for cerebellar development to proceed normally, thus illustrating the sensitivity of this process to the level of MDM2. Consistent with the well-established role of MDM2 as a negative regulator of p53 function, cerebellar defects in Mdm2puro/7-9 mice correlate with an increase in p53 protein expression and an elevated rate of p53-mediated apoptosis in GNPs in the EGL suggesting that p53 is responsible for the dearth of granule cells in adult cerebella. This interpretation is borne out by the complete rescue of all phenotypes of Mdm2puro/7-9 mice by deletion of p53, and establishes a critical role for MDM2 in negatively regulating wild-type p53 function during normal cerebellar development. As EGL expansion is a driving force of foliation [6], the inability of the EGL to expand appropriately, to the restricted number of GNPs in the Mdm2puro/7-9 cerebellum, likely underlies the foliation defects observed in these mice. These results implicate MDM2 as a major determinant of GNP cell survival and the extent of cerebellar foliation.

There is extensive cross-talk between GNPs and Purkinje cells in the developing cerebellum. Expansion of GNPs of the EGL is instructive for localization and differentiation of Purkinje cells [45]. Purkinje cells secrete Shh, which binds to and blocks the inhibitory activity of the Patch1 receptor expressed on GNPs, thereby driving GNP proliferation and EGL expansion [11,55]. Therefore, the failure of the EGL to expand in MDM2-deficient mice could either be due to a defect in GNPs or be secondary to a defect in Purkinje cells. While our work does not preclude a role for MDM2 in Purkinje cells, our results are consistent with an intrinsic requirement for MDM2 in GNPs. Several lines of evidence support this interpretation. (i) EGL expansion and foliation defects in Mdm2puro/7-9 cerebella coincide with p53-mediated apoptosis that is increased in GNPs but not in Purkinje cells. (ii) p53 expression is increased specifically in GNPs. (iii) There are approximately twice as many Purkinje cells per EGL cell in Mdm2puro/7-9 mice as in wild-type mice (P=0.002). (iv) Reduced expression of Gli1 and Gli2, important transducers of the Shh signal, in GNPs supports a cell autonomous disruption in Shh signaling. Thus, the Purkinje cell phenotype of Mdm2puro/7-9 mice is likely a consequence of the paucity of GNPs.

In cerebellar development, MDM2 deficiency mimics aspects of Shh deficiency. The decreased number of granule cells and shortened length of the folia of Mdm2puro/7-9 cerebella are reminiscent of the phenotypes of cerebella from mice with reduced Shh signaling. Shh-null mice lack cerebella [56], whereas mice in which Shh has been deleted in Purkinje cells (Shh−/−;L7-Cre) have cerebella of reduced complexity [11]. As adults these mice demonstrate decreases in cerebellar volume, short lobules, and a less cellular IGL [11], as do mice with reduced levels of MDM2 (Fig. 1). Mice lacking Gli2, which mediates Shh signaling [45,57], die before birth, precluding analysis of adult cerebella. However, by E18.5, Gli2−/− mice exhibit a cerebellum smaller than wild-type with a thinner, less proliferative EGL and diminished foliation, as do newborn, Mdm2puro/7-9 mice. When Gli2 has been conditionally deleted (Gli2-En1), mice survive to adulthood with small cerebella, short folia and a diminished IGL[45,57], as do Mdm2puro/7-9 mice. In contrast to Gli2, mice lacking Gli1 are phenotypically normal [50]. A role for Gli1 in the cerebellum is demonstrated however by the observation that loss of Gli1 further accentuates the foliation defects of the Gli2-deficient cerebellum [45,57]. Our data show that MDM2 regulates both Gli1 and Gli2 levels in GNPs supporting the concept that attenuated Shh signaling contributes, at least partially, to the foliation defects observed in Mdm2puro/7-9 cerebella.

Impaired foliation of Mdm2puro/7-9 cerebella is p53-dependent thereby implicating p53 in the regulation of Gli1 and Gli2 in GNPs. Recent studies in neural stem cells have demonstrated that p53 inhibits Gli1 in two ways: it reduces the nuclear localization and level of Gli1 protein and promotes phosphorylation of an N-terminally truncated form of Gli1, resulting in a less active isoform [49]. [49]. It is unknown whether p53 similarly inhibits Gli2. The mechanism(s) by which Gli1 and Gli2 is regulated by p53 in GNPs are an important area of future investigation.

The interconnections between the p53 and Shh pathways may be greater than previously surmised. We show that Shh signaling promotes the accumulation and phosphorylation of MDM2 in GNPs. Although the Shh target NMye binds to the Mdm2 gene and directly regulates Mdm2 transcription in neuroblastoma cell lines [59] we find that the level of total Mdm2 mRNA is not significantly increased following Shh stimulation of GNPs (Fig. 7C,D). The regulation of Mdm2 in GNPs also differs from that in C3H10T1/2 and MEFs in which Shh was shown to promote an increase in p-MDM2516S without a concomitant increase in MDM2 protein levels [60]. Thus, Shh signaling appears to regulate MDM2 function through different transcriptional and post-transcriptional mechanisms depending on cell type.

Elevated MDM2 function is predicted to keep basal p53 activity low. Indeed, deregulated SMO in C3H10T1/2 and MEFs promotes MDM2-mediated inhibition of p53 by enhancing the binding of MDM2 to p53, and abrogates p53-mediated growth arrest and apoptosis in response to DNA damage [60]. Conversely, p53-dependent apoptosis is increased in the retina and developing CNS of Shh−/− zebrafish embryos suggesting that p53 function is actively suppressed by Shh signaling [61]. These findings prompt us to speculate that in cancers in which the deregulation of Shh signaling is the initiating event, p53 function will be automatically inhibited, if only partially, through the enhancement of MDM2 activity by Shh signaling. If so, this mechanism may account for the infrequency of p53 gene mutations in childhood MB tumors. There is growing knowledge that genes important for development are also important for tumorigenesis. The inhibition of p53 through the up-regulation of MDM2 function in development may have broad implications for understanding the etiology of childhood embryonal tumors of the CNS that is thought to have a strong developmental component.

We present a model in which MDM2 is required to down-regulate p53 such that one or more Gli proteins is fully functional to transmit the Shh signal for GNP proliferation and tumorigenesis. In support of this model, expression of multiple Shh target genes is decreased in GNPs from mice with reduced levels of MDM2. We find that even a moderate, ~20% reduction in MDM2 is sufficient to attenuate Shh target gene expression, illustrating that Shh signaling in GNPs is sensitive to the level of MDM2 (Fig. 6A). Despite the attenuation of Shh signaling in mice with either ~50% or 80% the wild-type level of MDM2, gross defects in cerebellar development were observed only when the level of MDM2 was reduced to ~30% of the wild-type level. The
MDM2 and Shh in the Cerebellum

p53 and Shh pathways influence many physiological processes, including cell proliferation, survival, differentiation, and stem cell renewal [reviewed in 62,63]. The coordinate regulation of these two signaling pathways may be necessary during critical periods of development, allowing high levels of Shh-mediated proliferation without engaging p53 at a cell cycle checkpoint. Defective foliation in Mdm2−/− mice does not result in motor defects as measured here. Our results do not preclude the possibility that Mdm2 expression may be associated with human cerebellar defects. In people, there is a single nucleotide polymorphism in the Mdm2 gene that influences both Mdm2 gene expression and susceptibility to breast and other cancers [64]. It will be of interest to determine whether Mdm2 gene expression levels are associated with cerebellar hypoplasia or behavioral defects in people. Moreover, information about pathways regulating the ability of MDM2 to inhibit p53 may provide insight into the pathology of some congenital birth defects (e.g. Treacher Collins Syndrome) or chronic human diseases (e.g. Parkinson’s disease) for which there is growing evidence that heightened p53 activity in neuronal cells may be an important contributing factor [65,66,67].

While p53 is the most commonly mutated gene in human cancers, a large subset of tumors with wild-type p53 overexpress MDM2, an observation that has led to the development of targeted therapeutics designed to block the MDM2-p53 interaction [68]. This study demonstrates MDM2 promotes Shh-induced pre-neoplastic lesions in the cerebellum, suggesting that inhibition of MDM2 may be of high therapeutic value for the prevention or treatment of MB. However, our results also indicate that MDM2-targeted therapeutics may cause developmental defects. If MDM2 is found to be a critical component of pathways regulating MB in people, a cautious approach to MDM2 inhibition may be successful. Our results point to MDM2 as an important mediator of Shh signaling that may contribute to human medulloblastoma and its treatment.

Supporting Information

Table S1 (DOC)

Acknowledgments

We acknowledge the generosity of Tyler Jacks (Massachusetts Institute of Technology) and Karlyne Reilly (National Cancer Institute) in sharing p53−/− mice on 129/Sv and C57BL/6 backgrounds. We appreciate the expert technical assistance of Tamara Morgan and Scott Lawrence of the Laboratory for Animal Science Program at the National Cancer Institute and Tiwanda Maisinde and Natasha Clayton of the National Institute of Environmental Health Sciences Cellular and Molecular Pathology Branch. We thank our talented animal technicians, Nicole Morris, Debbie Peterson and Margaret Lauldi. We are grateful to Esta Sterneck for advice on earlier studies and to Barbara Shawke, Angy Hackett and Lori Davis for performing behavior studies. We thank Mark Lewandoski, Michael Kuehn, Karen Downs, Steve Konieczny, Allan Weissman, and Ronald Hullinger for comments on the manuscript.

Author Contributions

Conceived and designed the experiments: MEP SMM. Performed the experiments: RM JM NT. Analyzed the data: RM MEP SMM. Contributed reagents/materials/analysis tools: MEP SMM. Wrote the paper: MEP SMM.

References

1. Tanovan A, Grasso R, Gaglardi C, Trinick F, Bessoln N, et al. (2007) Disorders of cognitive and affective development in cerebellar malformations. Brain 130: 2646–2660.
2. Chizhikov V, Millen KJ (2003) Development and malformations of the cerebellum in mice. Mol Genet Metab 80: 34–45.
3. Wang YY, Rose MF, Zoghbi HY (2005) Math1 expression defines the rhombic lip derivatives and reveals novel lineages within the brainstem and cerebellum. Neuron 48: 31–43.
4. Goldwasser D, Hamre K (1999) The cells and molecules that make a cerebellum. Trends Neurosci 21: 375–382.
5. Wang YY, Zoghbi HY (2001) Genetic regulation of cerebellar development. Nat Rev Neurosci 2: 484–491.
6. Sudarov A, Jeyner AL (2007) Cerebellum morphogenesis: the foliation pattern is orchestrated by multi-cellular anchoring centers. Neural Dev 2: 26.
7. Millen KJ, Glesson JG (2008) Cerebellar development and disease. Curr Opin Neurobiol 18: 12–19.
8. Gilbertson RJ, Ellison DW (2008) The origins of medulloblastoma subtypes. Annu Rev Pathol 3: 341–365.
9. Dahnane M, Ruiz i Altaba A (1999) Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 126: 3089–3100.
10. Wechsler-Reya R, Scott MP (1999) Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 22: 103–114.
11. Lewis PM, Gritli-Linde A, Smeyne R, Kottmann A, McMahon AP (2004) Sonic hedgehog signaling is required for expansion of granule neuron precursors and patterning of the mouse cerebellum. Dev Biol 270: 393–410.
12. Marigo V, Daves RA, Zuo Y, Cunningham JM, Tabin CJ (1996) Biochemical evidence that patched is the Hedgehog receptor. Nature 384: 176–179.
13. Taipale J, Cooper MK, Maiti T, Beachy PA (2002) Patched acts catalytically to suppress the activity of Smoothened. Nature 416: 1892–1897.
14. Wechsler-Reya R, Scott MP (2001) The developmental biology of brain tumors. Annu Rev Neurosci 24: 383–428.
15. Kenney NM, Cole MD, Rowitch DH (2003) Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule precursor neurons. Development 130: 133–137.
16. Zhao Q, Kho A, Kenney AM, Yik DI, Kohane I, et al. (2002) Identification of genes expressed with temporal-spatial restriction to developing cerebellar neuron precursors by a functional genomic approach. Proc Natl Acad Sci U S A 99: 5704–5709.
17. Hahn H, Wicking C, Zaphiroplous PG, Gialani MR, Shanley S, et al. (1996) Mutations of the human homolog of Drosophila patched in the nevoid basal carcinoma syndrome. Cell 85: 841–851.
18. Goodrich LV, Milenkovic I, Higgins KM, Scott MP (1997) Altered neuronal cell fates and medulloblastoma in mouse patched mutants. Science 277: 1109–1113.
19. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, et al. (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425: 846–851.
20. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, et al. (2003) Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422: 313–317.
21. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts JJ, et al. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425: 851–856.
22. Kool M, Koster J, Bent J, Hasold NE, Lakeman A, et al. (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3: e3080.
23. Hallahan AR, Pritchard JA, Hansen S, Benson M, Stocke J, et al. (2004) The SmoA1 mouse model reveals that notch signalling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64: 7794–7800.
24. Cowan R, Hohan P, Kelsey A, Birch JM, Gattamaneni R, et al. (1997) The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 76: 141–145.
25. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JL, Eberhart CG, et al. (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559–1561.
26. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, et al. (2003) Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422: 313–317.
27. Marino S (2005) Medulloblastoma: developmental mechanisms out of control. Annu Rev Pathol 3: 341–365.
28. Kleihues P, Chaubale B, zur Hausen A, Esteve J, Ohgaki H, et al. (1997) Medulloblastoma: a tumor of the neuroepithelium. J Clin Oncol 15: 1755–1760.
29. Barel D, Avigad S, Mor C, Fogel M, Cohen IJ, et al. (1998) A novel germ-line mutation associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 152: 857–861.
30. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A (2000) Induction of p53 germline mutations: a synopsis of 91 families. Am J Pathol 152: 857–861.
32. Kastan MB, Zhan Q, de-Deir WS, Carrier F, Jacks T, et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597.

33. Yonish-Rouach E, Resniky D, Loretz J, Sachs I, Kimchi A, et al. (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345–347.

34. Jones SN, Roe AE, Donehower LA, Bradley A (1993) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206–208.

35. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.

36. Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, et al. (2007) The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol 213: 360–368.

37. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, et al. (2004) Chromosome expression and sustained cell cycle progression in mammalian neuronal development. Genes Dev 16: 2699–2712.

38. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, et al. (2003) mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462–472.

39. Jones SN, Roe AE, Donehower LA, Bradley A (1993) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206–208.

40. Kim JY, Nelson AL, Algon SA, Graves O, Sturla LM, et al. (2003) Trp53 mutant mice. Nat Genet 36: 63–68.

41. Crawley JN, Paylor R (1997) A proposed test battery and constellations of activity. Genes Dev 20: 16–21.

42. Hinds PW, Finlay CA, Frey AB, Levine AJ (1987) Immunological evidence for interleukin-6. Nature 352: 587–597.

43. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, et al. (2003) mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462–472.

44. Eszterhas SK, Bouhassira EE, Mao J, Kimchi A, et al. (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345–347.

45. Jones SN, Roe AE, Donehower LA, Bradley A (1993) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206–208.

46. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.

47. Knoepfler PS, Cheng PF, Eisenman RN (2002) N-myel oncoprotein: a new target for cancer therapy. J Clin Invest 110: 230–236.

48. Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, et al. (2007) The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol 213: 360–368.

49. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, et al. (2004) Chromosome expression and sustained cell cycle progression in mammalian neuronal development. Genes Dev 16: 2699–2712.

50. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, et al. (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345–347.

51. Mayo LD, Donner DB (2003) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98: 11598–11603.

52. Ogawa Y, Kishihara S, Ohara T, Isazawa Y, Suzuki T, et al. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277: 21843–21850.

53. Oliver TG, Read TA, Kessler JD, Mehmeti A, Wells JF, et al. (2005) Loss of patch and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 132: 2423–2439.

54. Kessler JD, Hasegawa H, Brn VN, Emmermager BA, Yang ZJ, et al. (2009) N- myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev 23: 157–170.

55. Smerse RJ, Chu T, Levin A, Bian F, Sanlioglu S, et al. (1995) Local control of granule cell generation by cerebellar Purkinje cells. Mol Cell Neurosci 6: 230–251.

56. Dahmann N, Sanchez P, Gitton Y, Palma V, Sun T, et al. (2001) The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 128: 5201–5212.

57. Kastan MB, Zhan Q, de-Deir WS, Carrier F, Jacks T, et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597.

58. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs I, Kimchi A, et al. (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345–347.

59. Jones SN, Roe AE, Donehower LA, Bradley A (1993) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206–208.

60. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.

61. Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, et al. (2007) The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol 213: 360–368.

62. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, et al. (2004) Chromosome expression and sustained cell cycle progression in mammalian neuronal development. Genes Dev 16: 2699–2712.

63. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, et al. (2003) mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462–472.

64. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Eisenman RN, et al. (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20: 16–21.

65. Kim Y, Alagon SA, Graves O, Sturla LM, et al. (2003) Malignant glioblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol 263: 56–66.

66. Craver JW, Paylor R (1997) A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horns Behav 31: 197–211.

67. Hindi PW, Finlay CA, Frey AB, Levine AJ (1987) Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol 7: 2801–2809.

68. Montgomery SM, McElwee MK, Michalowski J, Eisenman RN, et al. (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20: 16–21.

69. Eszterhas SK, Bouhassira EE, Martin DJ, Fiering S (2002) Transcriptional interference by independently regulated genes occurs in any relative arrangement of the genes and is influenced by chromosomal integration position. Mol Cell Biol 22: 469–479.

70. Corrales JD, Blaese R, Mahoney EM, Joyner AL (2006) The level of sonic hedgehog signaling regulates the complexity of cerebellar foliation. Development 133: 1811–1821.

71. Huard JM, Forster CC, Carter ML, Sicinski P, Ross ME (1999) Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development 126: 1927–1935.

72. Knoepfler PS, Cheng PF, Eisenman RN (2002) N-myel oncoprotein: a new target for cancer therapy. J Clin Invest 110: 230–236.

73. Kastan MB, Zhan Q, de-Deir WS, Carrier F, Jacks T, et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597.

74. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs I, Kimchi A, et al. (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345–347.